



# Mechanical Ventilation: State of the Art

Tài Pham, MD, PhD; Laurent J. Brochard, MD; and Arthur S. Slutsky, MD

## Abstract

Mechanical ventilation is the most used short-term life support technique worldwide and is applied daily for a diverse spectrum of indications, from scheduled surgical procedures to acute organ failure. This state-of-the-art review provides an update on the basic physiology of respiratory mechanics, the working principles, and the main ventilatory settings, as well as the potential complications of mechanical ventilation. Specific ventilatory approaches in particular situations such as acute respiratory distress syndrome and chronic obstructive pulmonary disease are detailed along with protective ventilation in patients with normal lungs. We also highlight recent data on patient-ventilator dyssynchrony, humidified high-flow oxygen through nasal cannula, extracorporeal life support, and the weaning phase. Finally, we discuss the future of mechanical ventilation, addressing avenues for improvement.

© 2017 Mayo Foundation for Medical Education and Research ■ Mayo Clin Proc. 2017;92(9):1382-1400



From the Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada; and Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.

In the 16th century, Andreas Vesalius provided what can be considered one of the first descriptions of endotracheal intubation and artificial ventilation, describing the insertion of a tube of reed into an animal's trachea and blowing air into the lungs to keep the animal alive.<sup>1,2</sup> Four centuries later, the iron lung<sup>3</sup> was the first negative-pressure ventilator successfully used in clinical practice. However, care of the patient was difficult using the iron lung because the patient's body was entirely enclosed in a metal tank. Hence, techniques that were remarkably similar to what Vesalius used were employed during the golden era of mechanical ventilation (MV), which was inaugurated during the poliomyelitis epidemics of the early 1950s. In Blegdams Hospital, Copenhagen, Denmark, Bjørn Ibsen, an anesthesiologist trained in Boston, Massachusetts, recommended tracheostomy and positive-pressure ventilation to treat patients with paralytic poliomyelitis.<sup>4</sup> Virtually overnight, mortality for these patients decreased from 87% to 40%.<sup>5</sup> Approximately 1500 medical students provided manual ventilation by squeezing rubber bags connected to endotracheal tubes for an estimated 165,000 hours.<sup>5</sup> For logistical reasons, these patients all received care in the same ward, essentially the first intensive care unit (ICU).

The difficulties with manual ventilation highlighted the need for mechanical devices, and both Claus Bang, a Danish physician,

and Carl-Gunnar Engström, a Swedish anesthesiologist, developed the first efficient mechanical ventilators.<sup>6</sup> The first arterial blood gas analyzers were built shortly thereafter. The next major step in the evolution of MV was the use of positive end-expiratory pressure (PEEP), mainly encouraged by the identification of the adult (acute) respiratory distress syndrome (ARDS) by Ashbaugh et al.<sup>7</sup> The Servo 900A (Siemens-Eléma) released in 1972 was the first mechanical ventilator with PEEP, and the servo valves controlling flow allowed the introduction of new modes of ventilation such as pressure-controlled ventilation and pressure support ventilation (PSV).<sup>8</sup> Ventilators became progressively more compact, user-friendly, and electronically based than pneumatic-based ventilators and incorporated a host of modes of ventilation and advanced monitoring capabilities.<sup>9</sup>

A recent epidemiological study estimated that in the United States, approximately 310 persons per 100,000 adult population undergo invasive ventilation for nonsurgical indications.<sup>10</sup> Despite this extensive use of MV, no precise recommendations exist summarizing when to initiate MV for acute respiratory failure. The main indications are (1) airway protection for a patient with a decreased level of consciousness (eg, head trauma, stroke, drug overdose, anesthesia), (2) hypercapnic respiratory failure due to airway, chest wall, or respiratory muscle diseases, (3) hypoxemic respiratory failure, or (4) circulatory failure,

in which sedation and MV can decrease the oxygen cost of breathing.

In this review, we provide an update on the principles underlying the management of MV for critically ill adult patients. We summarize the physiologic basis of MV, the interaction with the patient's physiology, and its major adverse effects and complications. We describe ventilation for specific patient groups such as those with ARDS<sup>11</sup> and chronic obstructive pulmonary disease (COPD), followed by an overview of the weaning phase. Finally, we briefly address the future of MV.

### BASIC PHYSIOLOGY

Understanding of the basic physiology of respiratory mechanics is necessary to optimally apply MV. Much of our progress in understanding and managing acute respiratory diseases comes from this understanding. The physiologic measurements obtained in the ventilated patient can be considered to be detailed pulmonary function testing and are available on a breath-to-breath basis.<sup>12</sup>

The forces at play during ventilation at any point in time are described by the equation of motion of the respiratory system. Pressure, volume, and flow changes during inspiration and expiration can be described by the simplified equation of motion of the respiratory system (Figure 1):  $P_{aw} = P_0 + (R \times \text{flow}) + (Vt \times E_{RS})$ , where  $P_{aw}$  = airway pressure (at the airway opening),  $P_0$  = initial alveolar pressure,  $R$  = resistance to flow,  $Vt$  = tidal volume, and  $E_{RS}$  = elastance of the respiratory system. Each term of this equation impacts the pressure applied to the airways.

$P_0$  is the alveolar pressure at the beginning of inspiration, which can be atmospheric pressure (termed *zero*) or greater than atmospheric (called *positive*). In patients with airway obstruction (eg, COPD), the expiratory time may be too short to allow the respiratory system to return to its relaxation volume. This aspect of airway obstruction can lead to intrinsic PEEP or auto-PEEP, a situation in which the alveolar pressure at the end of expiration is higher than the set PEEP. The airway pressure, measured by an end-expiratory occlusion (in a passive patients), is referred to as total PEEP.

$E_{RS}$  reflects the elastic characteristics of the respiratory system and is the inverse of


### ARTICLE HIGHLIGHTS

- Mechanical ventilation is “a necessary evil”: a lifesaving technique but with important potential complications.
- Decades of physiologic and clinical research have led to the concept of “protective ventilation” to minimize ventilation-induced lung injury but also minimize oxygen toxicity and optimize hemodynamics.
- Patient-ventilator dyssynchronies are frequent and associated with worse outcomes, but it is not clear whether they cause the poor outcomes or are a marker of severity of the underlying condition.
- Mechanical ventilation is part of a global strategy (“bundle”) and not a stand-alone treatment: sedation management, etiologic treatment, physiotherapy, and prevention of muscle loss are all important considerations in the ventilated patient.
- Minimizing the length of mechanical ventilation is the best way to minimize complications: as soon as mechanical ventilation is initiated, clinicians should consider how and when to discontinue its use; and throughout its course, decide which weaning strategy is most appropriate.

compliance of the respiratory system ( $C_{RS}$ ):  $E_{RS} = 1/C_{RS}$ . The airway pressure measured during an end-inspiratory occlusion is referred to as the plateau pressure (Pplat) and is a measure of the alveolar pressure, since the pressure drop due to airway resistance is zero at zero flow. Based on the equation of motion in the absence of flow (inspiratory pause),  $C_{RS} = Vt/(Pplat - P_0)$ .

Resistance ( $R$ ) represents the pressure difference required to generate a given flow. The resistance can be calculated in situations of constant (square) inspiratory flow as the difference between the peak inspiratory pressure and Pplat, divided by the flow ( $R = [\text{peak pressure} - Pplat]/\text{flow}$ ). The major part of the inspiratory resistance is often dominated by the resistance of the endotracheal tube.

Two simple maneuvers (end-inspiratory and end-expiratory occlusions) allow determination of the major physiological abnormalities of the respiratory system, which are characterized by high resistance ( $R$ ) and elevated total PEEP in COPD (or asthma), or high  $E_{RS}$  (low  $C_{RS}$ ) in ARDS (Figure 2).



**FIGURE 1.** Explanation of ventilator waves. Paw = airway pressure.

## WORKING PRINCIPLES OF MV MODES

### Phase Variables of a Breathing Cycle

The modes of MV are commonly defined by 4 elements determining the phases of the respiratory cycle (Table 1). The trigger phase initiates a breath. When the ventilation is fully controlled, the trigger variable is time, ie, a breath is initiated at fixed intervals. When the ventilator synchronizes the breath delivery with a signal related to the patient's effort, inspiration is initiated when a given flow or pressure decrease is detected by the ventilator. The target (or controlled) phase is the pressure or flow that will be maintained until the inspiration ends. The cycling phase determines the end of the inspiratory phase. A pressure, flow, or a preset time can cycle the breath. When the variable reaches the preset value, the passive expiratory phase starts. The expiratory control variable is usually a pressure (PEEP). Any given breath can involve a combination of the patient's breathing effort and a targeted pressure/flow delivered by the ventilator.<sup>13</sup> Breaths can therefore be (1) fully controlled—trigger and cycling are time controlled, the target variable is reached


passively, and the patient does not actively contribute to the breath; (2) partially supported or assisted—a combination of ventilator assistance and patient effort occurs in the same cycle; (3) unassisted—when the inspiratory flow is generated entirely by the patient's respiratory muscles (Table 1).

### Influence on Respiratory Muscle Activity and Importance of Synchrony

Measures of a patient's effort are usually not available during MV. Complex measurements are needed to determine the patient's work of breathing or the pressure-time product, both requiring an esophageal catheter<sup>14</sup>; the oxygen cost of breathing requires measurements of oxygen consumption. During respiratory distress, the patient's work of breathing can be increased up to 6-fold<sup>15</sup>; a major goal of MV is to reduce this work. The patient's respiratory drive is modulated via chemoreceptors and modulated by sedation and by PaO<sub>2</sub>, pH, and PaCO<sub>2</sub>. The trigger sensitivity and the inspiratory peak flow also have an important influence on the respiratory drive and work of breathing.<sup>16-19</sup>

A fundamental but as yet unresolved question is to what extent a patient's work of breathing should be reduced by a particular ventilatory strategy. It is important to relieve dyspnea, decrease the oxygen consumption of the respiratory muscles, and avoid injury to these muscles. However, there is a growing body of evidence suggesting that excessive unloading can lead to muscle dysfunction and atrophy, with subsequent weaning difficulties.<sup>20</sup> During the acute phase of the patient's illness, the patient's effort needs to be decreased or suppressed. Over the recovery period, ascertaining the optimal balance between the patient's effort and ventilator assistance is challenging for the clinician, in part because of a lack of adequate monitoring and also a lack of data about the optimum ratio of effort to assistance.

Patient-ventilator dyssynchrony, defined as a mismatch between the patient's inherent inspiratory and expiratory times and those delivered by the ventilator, is a frequent problem during MV, occurring in about one-third of patients.<sup>21-25</sup> There are a number of different types of dyssynchronies during invasive<sup>24-26</sup> and noninvasive<sup>27,28</sup> ventilation,



which are summarized in Table 2. Figure 3 presents an example of a ventilator monitor displaying reverse triggering with double cycling. Often, these dyssynchronies indicate a mismatch between the ventilatory needs of the patient and the amount of ventilation delivered. Although association does not imply causality, patients with greater numbers of dyssynchronies have poorer outcomes including longer durations of ventilation, longer ICU stays, and higher mortality.<sup>26,29,30</sup> In some cases, this worse outcome may be explained by increased  $V_t$ s, breath stacking, intrinsic PEEP,<sup>31</sup> or regional hyperinflation,<sup>32</sup> but dyssynchronies may also be a marker of

the severity of the underlying lung pathophysiology. Although improving patient-ventilatory synchrony makes intuitive sense, we lack definitive data proving that it improves patients' outcomes.

#### COMPLICATIONS OF MV

Mechanical ventilation is often lifesaving but is associated with serious complications, in part because it is delivered to patients at high risk of lung or cardiac compromise. These complications may be related to the direct mechanical effects of the intrathoracic pressures generated by the ventilator, to alveolar and systemic inflammation, or to neural stimulation. There

**TABLE 1. Main Ventilator Modes and Settings**

Mode	Variable									
	Trigger	Cycling	Inspiratory pressure	Tidal volume	Respiratory rate	Minute ventilation	Plateau pressure	Driving pressure	PEEP	FIO <sub>2</sub>
Ranges of values or settings	1 to 5 L/min −0.5 to −3 cm H <sub>2</sub> O	1 second 30%-70% peak flow	10-30 cm H <sub>2</sub> O	~200-600 mL 4-8 mL/kg PBW	10-35 min <sup>-1</sup>	~7-12 L/min	15-35 cm H <sub>2</sub> O	8-20 cm H <sub>2</sub> O	0-22 cm H <sub>2</sub> O	0.21-1.0
A/C in volume (or VC-CMV)	Time (controlled cycles) Flow or pressure (assisted cycles)	Time	Dep Var	V	V/P	Dep Var	Dep Var	Dep Var	V	V
A/C in pressure (or PC-CMV)	Time (controlled cycles) Flow or pressure (assisted cycles)	Time	V	Dep Var	V/P	Dep Var	V	V	V	V
PSV (CSV)	Flow or pressure	Flow	V	Dep Var	P	P	V/P	V/P	V	V
SIMV (VC or PC-IMV)	Time (controlled cycles) Flow or pressure (assisted cycles)	Time Flow	V/P	V/P	V/P	Dep Var	V/P	V/P	V	V
PRVC (PC-CMV)	Time (controlled cycles) Flow or pressure (assisted cycles)	Time	V/P	V/P	V/P	Dep Var	V	V	V	V
APRV (PC-IMV)	Time (controlled cycles)	Time	V	Dep Var	V/P	Dep Var	V	V	V	V
PAV (CSV)	Flow or pressure	Flow	P (in proportion to inspiratory effort)	P	P	P	NA	NA	V	V
NAVA (CSV)	EaDi	EaDi	P (in proportion to inspiratory effort)	P	P	P	NA	NA	V	V
CPAP (CSV)	Flow or pressure	Flow or pressure	V	P	P	P	NA	NA	V	V
Suggested settings	Minimal value with no autotriggering	High % in obstructive lung disease, low in restrictive disease	NA	6 mL/kg PBW	NA	NA	Keep <30	Less than ~14 associated with better outcome	≥5	Minimal to keep SpO <sub>2</sub> 90%-94%
Color	Meaning									
P	Controlled by the patient									
V	Controlled by the ventilator									
V/P	Can be controlled either by the patient or the ventilator									
Dep Var	Dependent variable to be monitored (dependent on respiratory mechanics and effort)									

A/C = assist-control; APRV = airway pressure release ventilation; CMV = continuous mandatory ventilation; CPAP = continuous positive airway pressure, with no inspiratory assistance above the set pressure level; CSV = continuous spontaneous ventilation; Dep Var = dependant variable; EaDi = electrical activity of the diaphragm; FIO<sub>2</sub> = inspired fraction of oxygen; IMV = intermittent mandatory ventilation; NA = not applicable; NAVA = neurally adjusted ventilatory assist (see text); P = patient; PAV = proportional assist ventilation (see text); PBW = predicted body weight; PC = pressure control; PEEP = positive end-expiration pressure; PRVC = pressure-regulated volume control, which delivers pressure-targeted breaths, varying from breath to breath to reach a target volume; PSV = pressure support ventilation; SIMV = synchronized intermittent mandatory ventilation, which mixes mandatory breaths and pressure support breath (PSV) each minute; SpO<sub>2</sub> = pulsed oximetry oxygen saturation; V = ventilator; VC = volume control.  
Abbreviations adapted from *Respir Care*.<sup>13</sup>

is evidence of cross-talk between the lung and the brain and between the lung and the kidneys, all influenced by MV.<sup>33,34</sup> Many of the complications of MV can potentially be avoided or minimized. This factor is important from a clinical perspective and is a major area of current research.

### Initiation of MV

Endotracheal intubation is a critical procedure in which patients are at risk of respiratory and/or circulatory compromise.<sup>35,36</sup> Before intubation, the patient should be assessed for factors indicating a possible difficult intubation; there are specific scoring systems for the ICU.<sup>37</sup> Pre-oxygenation is essential, and different techniques such as noninvasive ventilation (NIV)<sup>38</sup> or high flow delivered via nasal cannula have been proposed for patients with the most severe disease. To avoid gastric aspiration, rapid-sequence intubation using a sedative drug and a neuromuscular blocking agent is often recommended.<sup>39</sup> Recommendations and algorithms have been developed for patients with a “difficult airway”.<sup>40,41</sup>

### Hemodynamic Effects

Positive-pressure ventilation has long been known to have hemodynamic effects through heart-lung interactions. These effects have been better understood, managed, and often prevented over the past few decades by an increased understanding of the following mechanisms. First, high intrathoracic pressure, especially high plateau pressures can negatively impact right ventricular afterload and function.<sup>42</sup> Our understanding of auto-PEEP and the use of protective lung ventilation have markedly reduced the incidence of hemodynamic complications through the use of lower volumes and pressures.<sup>43,44</sup> Echographic studies in patients with ARDS have reported a prevalence of acute cor pulmonale of about 22%,<sup>45,46</sup> which is still quite high, but markedly lower than previously reported.<sup>44,47</sup> Second, hypotensive effects of sedative agents acting via negative inotropy, vasodilation, or central mechanisms are managed by appropriate use of vasoactive drugs or fluids. Third, the use of partial ventilatory assist reduces intrathoracic pressures and minimizes sedation needs, facilitating the hemodynamic tolerance of MV. Finally, pulmonary hypertension

and PEEP, especially in patients with ARDS, can result in a right-to-left shunting across a patent foramen ovale and worsen hypoxemia in up to 20% of patients with ARDS.<sup>48</sup>

### Complications of Sedation

In the early phase of MV, sedation with or without paralysis is often required, especially for patients with shock or ARDS or for those “fighting the ventilator.”<sup>49</sup> The slow metabolism of sedative agents may unduly prolong the duration of MV and lead to detrimental short- and long-term outcomes.<sup>50,51</sup> Each sedative agent has specific effects, and the appropriate choice of the type and dose of sedative drugs may impact outcome. Data suggest that benzodiazepines are particularly associated with poorer long-term outcomes.<sup>52</sup> Propofol is frequently used because of a relatively short half-life, but there are concerns associated with prolonged infusion.<sup>53</sup> Dexmedetomidine has been proposed as a promising alternative to usual sedation because it reduces the rate of delirium,<sup>54,55</sup> but results from clinical trials have not been consistent. If sedation cannot be avoided, it is important to carefully monitor the depth of a patient’s sedation and to use a sedation protocol, including daily interruption of sedation to avoid a state of deep sedation.<sup>56,57</sup>

### Oxygen Toxicity

Mechanical ventilation allows patients to receive a fraction of inspired oxygen (FIO<sub>2</sub>) of up to 1.0, which may be necessary for patients with severe hypoxemia. However, high levels of oxygen have toxic effects, which have been a concern since the early days of MV.<sup>58</sup> In low ventilation-perfusion ratio lung units, high FIO<sub>2</sub> can lead to reabsorption atelectasis,<sup>59</sup> which can be minimized using higher levels of PEEP.<sup>60</sup> Oxygen also has extrapulmonary effects—it can decrease cardiac output by decreasing parasympathetic tone<sup>61</sup> and increasing vascular resistance, and it has vasoconstrictive effects on cerebral and coronary perfusion.<sup>62,63</sup> Several studies have suggested an independent association between hyperoxemia and hospital mortality in some groups of patients (eg, those with cardiac arrest or stroke).<sup>64</sup> Clinicians, however, tend to be much more sensitive to hypoxemia than to hyperoxemia. Recent preliminary

TABLE 2. Main Patient-Ventilator Dyssynchronies and Interactions

Dyssynchrony or patient-ventilator interaction	Description	Pathophysiology	Risks	Main modes of MV	Suggestions
During inspiration					
Flow starvation	Delivered flow does not match patient's demand	<ul style="list-style-type: none"> <li>• Insufficient peak flow</li> <li>• High respiratory drive</li> </ul>	<ul style="list-style-type: none"> <li>• Dyspnea</li> <li>• High levels of work of breathing</li> </ul>	<ul style="list-style-type: none"> <li>• A/C ventilation (volume)</li> </ul>	<ul style="list-style-type: none"> <li>• Increase peak flow &gt;50 L/min (direct setting or shorten inspiratory time to obtain the same volume faster)</li> </ul>
Short cycles	Continuation of inspiratory effort after the end of insufflation	<ul style="list-style-type: none"> <li>• Insufficient inspiratory time</li> <li>• High respiratory drive</li> </ul>	<ul style="list-style-type: none"> <li>• Eccentric contractions of respiratory muscles</li> <li>• Double triggering</li> </ul>	<ul style="list-style-type: none"> <li>• A/C ventilation (pressure or volume)</li> </ul>	<ul style="list-style-type: none"> <li>• Increase inspiratory time</li> </ul>
Prolonged insufflation	Continuation of insufflation after the end of inspiratory effort	<ul style="list-style-type: none"> <li>• Inadequate cycling mechanism</li> <li>• Gas trapping</li> </ul>	<ul style="list-style-type: none"> <li>• Shorten neural expiration and promote gas trapping</li> <li>• Dyspnea</li> </ul>	<ul style="list-style-type: none"> <li>• A/C ventilation (pressure)</li> <li>• PSV</li> <li>• NIV</li> </ul>	<ul style="list-style-type: none"> <li>• Modify cycling to make the inspiration shorter</li> </ul>
Reverse triggering	Diaphragmatic contraction triggered by mechanical insufflation	Reflex mechanism in highly sedated patient	<ul style="list-style-type: none"> <li>• Loss of protective ventilation</li> <li>• Monitoring of plateau pressure inoperative</li> <li>• Eccentric contractions of respiratory muscles</li> </ul>	<ul style="list-style-type: none"> <li>• A/C ventilation (pressure or volume)</li> </ul>	<ul style="list-style-type: none"> <li>• Paralyze if VT too high or double cycle</li> <li>• Decrease sedation</li> </ul>
Double cycles (during inspiration or expiration)					
Double cycles after reverse triggering	Reverse triggering of a second cycle	Reflex mechanism in highly sedated patient	<ul style="list-style-type: none"> <li>• Double the mechanical stress on the lung</li> </ul>	<ul style="list-style-type: none"> <li>• A/C ventilation (pressure or volume)</li> </ul>	<ul style="list-style-type: none"> <li>• Paralyze if VT too high or double cycle</li> <li>• Decrease sedation</li> </ul>
Double (or triple) triggering after short cycles (breath stacking)	Continuation of inspiratory effort after the end of insufflation	<ul style="list-style-type: none"> <li>• Insufficient inspiratory time</li> <li>• High respiratory drive</li> </ul>	<ul style="list-style-type: none"> <li>• Double or triple the mechanical stress on the lung</li> </ul>	<ul style="list-style-type: none"> <li>• A/C ventilation (pressure or volume)</li> <li>• PSV</li> </ul>	<ul style="list-style-type: none"> <li>• Increase inspiratory time</li> <li>• Increase VT</li> <li>• Modify cycling to make the inspiration longer</li> </ul>
During expiration					
Autotriggering	Cycles not triggered by the patient	<ul style="list-style-type: none"> <li>• Leaks</li> <li>• Water in the circuit</li> <li>• Excessively sensitive trigger</li> <li>• Cardiac oscillations</li> </ul>	<ul style="list-style-type: none"> <li>• Dyspnea</li> <li>• Misleading information on breathing pattern</li> <li>• Severe hyperventilation (eg, arrhythmias, reduced cerebral blood flow)</li> <li>• Increase rate of lung stress</li> </ul>	<ul style="list-style-type: none"> <li>• A/C ventilation (pressure or volume)</li> <li>• PSV</li> <li>• NIV</li> </ul>	<ul style="list-style-type: none"> <li>• Inspect tubing</li> <li>• Decrease trigger sensitivity</li> </ul>

Continued on next page

TABLE 2. Continued

Dyssynchrony or patient-ventilator interaction	Description	Pathophysiology	Risks	Main modes of MV	Suggestions
During expiration, continued Gas trapping	Next inspiration starts before end of exhalation	High time constant	<ul style="list-style-type: none"> <li>Poor diaphragm function</li> <li>Hemodynamic effects</li> <li>Ineffective efforts</li> </ul>	<ul style="list-style-type: none"> <li>Any assisted mode</li> <li>NIV</li> </ul>	Decrease hyperdynamic inflation: <ul style="list-style-type: none"> <li>Increase expiration time</li> <li>Decrease minute ventilation (decreased VT and/or RR)</li> <li>Decrease frequency</li> </ul>
Ineffective effort	Effort unable to trigger the ventilator	<ul style="list-style-type: none"> <li>Inadequate cycling</li> <li>Excessive support</li> <li>Large time constant</li> <li>Low respiratory drive</li> </ul>	<ul style="list-style-type: none"> <li>Repeated pleiometric work</li> <li>Erroneous display of respiratory rate</li> <li>Prolonged duration of ventilation</li> </ul>	<ul style="list-style-type: none"> <li>Any assisted mode</li> <li>NIV</li> </ul>	<ul style="list-style-type: none"> <li>Increase trigger sensitivity</li> <li>Decrease sedation</li> <li>Increase expiration time</li> <li>Increase PEEP (to equal intrinsic PEEP)</li> </ul>

A/C = assist-control; MV = mechanical ventilation; NIV = noninvasive ventilation; PEEP = positive end-expiratory pressure; PSV = pressure support ventilation; RR = respiratory rate; VT = tidal volume.

data suggest that conservative oxygen therapy targeting a PaO<sub>2</sub> of 70 to 100 mm Hg or a pulse oximetry oxygen saturation (SpO<sub>2</sub>) of 94% to 98% results in lower ICU mortality than a conventional, more “liberal” approach with higher PaO<sub>2</sub> and SpO<sub>2</sub> targets.<sup>65</sup>

**Effects on Respiratory Muscles and Respiratory Infections**


Mechanical ventilation has been associated with respiratory muscle dysfunction and weaning difficulties.<sup>20,66-68</sup> Disuse atrophy of the diaphragm appears to be a key mechanism for these detrimental effects, suggesting the need to better monitor respiratory muscle activity. Partial modes of ventilation do not always prevent this atrophy. Several studies examining diaphragm biopsies have found that changes in structure occur early after intubation.<sup>66</sup> More than 50% of patients experience dysfunction related to an excessive level of assistance (controlled or partial ventilation) or to insufficient assistance.<sup>67</sup> Limb muscle weakness, referred to as ICU-acquired weakness, and diaphragm dysfunction have only minimal overlap. Respiratory muscle dysfunction is at least twice as prevalent as limb muscle weakness at the time of separation from MV and has a strong impact on weaning.<sup>20</sup>

Intubated and ventilated patients are at risk for ventilation-acquired pneumonia due to microaspiration from the oropharyngeal cavity and diminished host defense due to decreased cough efficiency and impaired mucociliary clearance. Recent guidelines recommend limitation of sedation and shortening the duration of MV in order to minimize the risk of ventilation-acquired pneumonia.<sup>69</sup>

**Ventilator-Induced Lung Injury**

Mechanical ventilation can induce or worsen lung injury, referred to as ventilator-induced lung injury (VILI).<sup>70-75</sup> This disorder has become a major concern in the modern era of MV, profoundly modifying the clinical targets of MV. Ventilator-induced lung injury may impact a large number of patients, most specifically those with or at risk for ARDS. Prevention is described in greater detail in the “Acute Respiratory Distress Syndrome” section.





**FIGURE 3.** Tracings of airway pressure (Paw), flow, and volume in a sedated patient undergoing assist-control mechanical ventilation, depicting classic and frequent dyssynchrony of double cycling. Despite a set rate of 20/min, the actual rate is 40/min. Diaphragmatic electrical activity signal (EaDi), superimposed on the Paw curve, provides the mechanism, called reverse triggering. Diaphragmatic contractions are triggered by the mechanical insufflations on a 1:1 basis and explain the second cycle. Patient-trig = patient-triggered occurring after each mandatory breath; Time-trig = time-triggered.

### Long-term Consequences

Mechanical ventilation of at least one week's duration is associated with important consequences on the long-term physical, cognitive, and mental health of ICU survivors.<sup>76</sup> Whether this condition, sometimes referred to as the post-intensive care syndrome,<sup>77</sup> is specific to MV or a manifestation of critical illness is unclear. For instance, cognitive impairment is a devastating complication in ICU survivors, with 26% of patients having a cognitive score 1 year after ICU admission, similar to patients with mild Alzheimer disease.<sup>78</sup> It is likely that the impairment is multifactorial, including factors such as the patient's pre-ICU trajectory, severity of illness, sedation, delirium, and sleep disruption<sup>79,80</sup> linked to MV.<sup>81</sup>

Survivors of ICU care who have undergone prolonged MV (more than 2 weeks)

have an in-hospital mortality of 30% and a 1-year mortality rate as high as 60%.<sup>82</sup> Interestingly, most ARDS survivors regain virtually normal pulmonary function in a few months, but their major functional disabilities are often a consequence of ICU-acquired weakness and complications of bed rest.<sup>83</sup> A recent study also found that caregivers of patients with prolonged ventilation had increased depressive symptoms 1 year after ICU discharge.<sup>84</sup>

### MAIN VENTILATOR SETTINGS

Assist-control ventilation using volume or pressure as the target and PSV are currently the 3 main modes of ventilation used worldwide.<sup>85,86</sup> These modes allow the clinician to set FIO<sub>2</sub>, PEEP, and a target variable (pressure or volume). There is, however, a wide variety of pressure-controlled modes, including airway pressure release ventilation or dual modes, which has been addressed elsewhere.<sup>13,87</sup>

### Oxygenation

Although FIO<sub>2</sub> can be set from 0.21 to 1.0, it should be set at the lowest value required to reach the oxygenation target. This target varies from patient to patient, but an SpO<sub>2</sub> of 92% to 96% is a reasonable goal. Of note, in patients with a large shunt, increasing FIO<sub>2</sub> has only minimal impact on arterial oxygenation.

PEEP can be adjusted to improve oxygenation in patients with collapsed lung units (eg, patients with ARDS), mainly by increasing functional residual capacity. In recruitable lungs, PEEP can maintain open recruited lung areas and hence reduce repeated alveolar opening and closure.<sup>88</sup> PEEP can also lead to overdistention of the more compliant areas of the lungs and can decrease cardiac output and oxygen delivery even in the presence of an increased PaO<sub>2</sub>.<sup>89</sup>

### Ventilation

The target variable for assist-control ventilation can be volume or pressure; neither has proven to be superior in terms of outcome.<sup>90</sup> Pressures must be monitored when the Vt is set, and volumes must be monitored when the pressure is set. Table 1 provides a summary of possible settings based on the mode of MV.

In the past, a major goal of MV was to ensure that patients had normal arterial blood gas levels, with little regard to the harms caused by MV. Currently, a priority is to ensure that VILI is minimized while maintaining adequate, but not necessarily normal, gas exchange. The best oxygenation is not always the most protective, and moderate levels of hypercapnia are considered acceptable. In the past, high V<sub>t</sub>s were recommended on the basis of studies in anesthetized patients that found that small V<sub>t</sub>s led to atelectasis and hypoxemia.<sup>91</sup> Atelectasis was related to the combined effects of high FIO<sub>2</sub>, anesthesia, and lack of PEEP. It took years of research to realize that high V<sub>t</sub>s, despite having favorable effects on oxygenation, were harmful for the lungs and increased mortality.<sup>92</sup>

Current recommendations for setting V<sub>t</sub> are based on predicted body weight (PBW) and not actual body weight because (normal) lung size scales with PBW. One formula is: PBW (kg) = 50.0 + 0.91 (height in cm – 152.4) for males and PBW (kg) = 45.5 + 0.91 (height in cm – 152.4) for females. The recommended range is 6 to 8 mL/kg PBW.

Partial modes of assist are very popular, based on the delivery of a pressure support level. They are frequently used and generally well tolerated.<sup>93</sup> There are 2 concerns with these modes. One is that patients can be easily overassisted<sup>29,94</sup>; experimental<sup>68</sup> and clinical<sup>67</sup> data suggest that despite the use of partial support, insufficient muscle use can lead to atrophy and dysfunction. Second, because the V<sub>t</sub> cannot be controlled, patients with high respiratory drive may generate excessive V<sub>t</sub>s, which can lead to a form of patient self-inflicted lung injury.<sup>95,96</sup>

### Proportional Modes of Ventilation

Two modes of ventilation are based on a different principle and address some of the concerns discussed previously. These 2 modes, which require a relatively preserved neuroventilatory drive, deliver pressure in proportion to the patient's demand and let the patient regulate V<sub>t</sub>. One mode called proportional assist ventilation requires real time calculation of the equation of motion of the respiratory system based on automated measurements of respiratory system compliance and resistance. The second mode uses the

electrical activity of the diaphragm and is called neurally adjusted ventilatory assist (NAVA). The only setting required from the clinician is the amount of assistance: during proportional assist ventilation, it is set as a percentage of assistance, and for neurally adjusted ventilatory assist, it is set by the proportionality factor between electrical activity of the diaphragm and pressure. For both modes, V<sub>t</sub>, frequency, and pressure are not set by the clinician. Both modes are very effective in reducing dyssynchronies and in adapting to changes in ventilatory demand, explaining improvement in sleep quality observed with their use.<sup>97-99</sup> However, few outcome data are available.<sup>100,101</sup> Some experimental or human data suggest that they may allow a safer control of ventilation than routine lung protective ventilation.<sup>102,103</sup>

### ACUTE RESPIRATORY DISTRESS SYNDROME

No other ICU syndrome has been studied as much as ARDS. Understanding the impact of MV on patients with ARDS has resulted in major changes in ventilator management over the past 25 years.

A consensus definition of ARDS was released in 1994, more than 25 years after its initial description.<sup>104</sup> The most recent Berlin definition tried to overcome some of the limitations of previous definitions.<sup>11,105</sup> ARDS is currently defined by a new onset or worsening of respiratory symptoms with bilateral opacities on chest radiography and a PaO<sub>2</sub>:FIO<sub>2</sub> ratio 300 mm Hg or less while receiving PEEP of 5 cm H<sub>2</sub>O or higher. Concomitant heart failure can be present, but if no known risk factor for ARDS has been identified, congestive heart failure must be objectively ruled out.

There are many predisposing factors that can lead to the development of ARDS, but the lungs of patients with ARDS share several common biological, cellular, and mechanical characteristics. The lungs are edematous and heavy, adding considerable superimposed pressure to the dependent lung regions. Normally aerated tissue is greatly reduced and has been described as a “baby lung.”<sup>106,107</sup> The baby lung concept explains the low respiratory system compliance, high pressures, and high risk for VILI. Minimizing

the risk of VILI has improved survival.<sup>70,74,108</sup> In contrast, pharmacological approaches for treating ARDS have been disappointing.

Different techniques have been used to try to prevent intubation in patients with acute hypoxemic respiratory failure, including NIV. A high-flow nasal cannula is used increasingly in patients with acute hypoxemic respiratory failure and has improved comfort, decreased dyspnea, and decreased mouth and airway dryness sensation compared with conventional oxygen therapy.<sup>109,110</sup> A recent study found a similar rate of intubation but a reduced mortality rate in the group of patients treated with high-flow nasal cannula compared with NIV or standard oxygen.<sup>111</sup> Intubation was reduced in those with a PaO<sub>2</sub>:FIO<sub>2</sub> ratio lower than 200 mm Hg. It may work in part by reducing the oropharyngeal dead space by a washout effect and by increasing end-expiratory pressure.<sup>112</sup>

The Acute Respiratory Distress Syndrome Network Lower Tidal Volume (ARMA) trial was the first large multicenter clinical trial to document the benefit of a lung protective strategy using lower than traditional V<sub>t</sub>s (~6 mL/kg PBW) and limiting P<sub>plat</sub> to 30 cm H<sub>2</sub>O.<sup>113</sup> Since then, accumulating evidence has demonstrated that low V<sub>t</sub>s, with or without a certain degree of acidosis (permissive hypercapnia), are efficient in limiting VILI.<sup>114</sup> Reducing instrumental dead space (eg, filters) is necessary, and increasing the respiratory rate to 35 breaths/min is recommended to minimize hypercapnia. There is some evidence that decreasing V<sub>t</sub> even further may improve outcomes.<sup>115</sup> Clinical trials are exploring the impact of lower V<sub>t</sub>s using extracorporeal circulation to remove carbon dioxide.<sup>116</sup>

How to best set the PEEP level for any patient has been a matter of debate for 5 decades. The initial focus was to improve oxygenation with higher PEEP, but the current thinking is that any improvement in outcomes with higher PEEP levels is due to decreased VILI. Individual trials have failed to document decreased mortality with a higher PEEP strategy,<sup>71,117,118</sup> but an individual patient data meta-analysis found that higher PEEP was associated with a 5% lower mortality rate in patients with moderate or severe ARDS (PaO<sub>2</sub>:FIO<sub>2</sub> ratio <200 mm Hg) but not in

patients with a PaO<sub>2</sub>:FIO<sub>2</sub> ratio higher than 200 mm Hg.<sup>73</sup> The high PEEP strategy improved several secondary end points such as hypoxemia, use of rescue therapies, and duration of organ failure and MV.

Measurement of esophageal pressure to estimate transpulmonary pressure at end-expiration is a promising approach.<sup>119,120</sup> A strategy titrating PEEP on the basis of transpulmonary pressures revealed improved oxygenation and compliance compared with standard settings,<sup>121</sup> and a larger clinical trial of this approach is currently ongoing (NCT01681225).

Recently, a reanalysis of 9 of the main randomized controlled trials (RCTs) in ARDS compared the impact of V<sub>t</sub>, PEEP, P<sub>plat</sub>, and driving pressure ( $\Delta P = P_{plat} - PEEP$ ) on outcomes. Driving pressure change was the variable that best predicted mortality,<sup>122,123</sup> perhaps because it is equal to (V<sub>t</sub>/C<sub>RS</sub>)—ie, V<sub>t</sub> normalized to respiratory system compliance, the latter being related to lung size. Conversely, PBW is a good predictor of lung size in healthy individuals but not in patients with ARDS, who can have markedly decreased lung volumes. The recent international multicenter observational LUNG SAFE (Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure) study also found an association between both higher P<sub>plat</sub> and  $\Delta P$  with mortality.<sup>86</sup> These studies suggest that a safe ventilatory strategy should first use a V<sub>t</sub> of 6mL/kg PBW, while limiting plateau and driving pressure. Keeping  $\Delta P$  below a risky level (eg, <15 cm H<sub>2</sub>O) may help, although no prospective data are available. High PEEP levels (>10-15 cm H<sub>2</sub>O) seem beneficial in moderate and especially severe ARDS (PaO<sub>2</sub>:FIO<sub>2</sub> ratio <200 mm Hg).

In moderately severe to severe ARDS with a PaO<sub>2</sub>:FIO<sub>2</sub> ratio of less than 150 mm Hg, adjunctive therapies such as neuromuscular blockade for the first 48 hours<sup>49</sup> or prone positioning also result in improved survival.<sup>124,125</sup> Implementation of the prone position requires training by the clinical team, but the evidence strongly suggests that it should be applied when the PaO<sub>2</sub>:FIO<sub>2</sub> ratio remains lower than 120 mm Hg despite protective ventilation.

Extracorporeal membrane oxygenation may be beneficial in patients with the most severe ARDS and is currently under

investigation. The results of the EOLIA (Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome) trial ([ClinicalTrials.gov](https://clinicaltrials.gov) Identifier: NCT01470703) will provide valuable information.<sup>126,127</sup> At present, it seems reasonable to apply extracorporeal membrane oxygenation if prone positioning is ineffective.

Alveolar recruitment techniques vary and may have adverse effects. Recent data indicate that most of the effect of a sustained inflation (35-40 cm H<sub>2</sub>O) is obtained after 10 seconds, suggesting that such maneuvers can be terminated relatively early before adverse events occur.<sup>128</sup> Even if recruitment maneuvers substantially improve oxygenation, this effect is transient, and the benefit on patient outcomes is still controversial.<sup>129,130</sup>

Two RCTs using high-frequency oscillation found no benefit for moderate and severe ARDS, and one of them even found a higher mortality rate for patients treated with this technique.<sup>131,132</sup> Therefore, high-frequency oscillation is not recommended as first-line therapy for patients with ARDS. However, a recent meta-analysis suggests that it may be beneficial in very severely hypoxemic patients.<sup>133</sup> Inhaled nitric oxide can lead to vasodilation of the well-ventilated alveoli with subsequent improvement in oxygenation but has been found in multiple studies to not impact mortality and may have adverse effects such as increased risk of renal dysfunction.<sup>134,135</sup>

### PROTECTIVE VENTILATION FOR PATIENTS WITH RELATIVELY NORMAL LUNGS

There is accumulating evidence for the beneficial effects of lung protective ventilation in patients without ARDS,<sup>136</sup> including those undergoing major surgical procedures, patients without ARDS at presentation, and in brain-dead patients who are potential lung donors.

For surgical patients with previously healthy lungs, the conventional strategy has previously been to combine high V<sub>t</sub> (~10-15 mL/kg) with high FIO<sub>2</sub> using low or no PEEP. The goal with this strategy was to prevent atelectasis.<sup>137,138</sup> In recent years, several studies have examined lung protective ventilation strategies (low V<sub>t</sub>, PEEP with or without recruitment maneuvers) in the operating room. One study reported a 3-fold

reduction in postoperative complications and in the requirement of postoperative MV with this strategy compared with conventional ventilation in patients undergoing major abdominal operations.<sup>139</sup> Other studies in patients undergoing thoracic and abdominal surgical procedures have documented reduced postoperative pulmonary and extrapulmonary complications with lower health care utilization when a protective ventilation strategy was used.<sup>139,140</sup> Protective ventilation is not associated with additional risk of intraoperative complications.

In intubated ICU patients not presenting with ARDS on admission, a strategy using lower V<sub>t</sub> was associated with shorter duration of MV.<sup>141</sup> A meta-analysis examining surgical and ICU patients found that lower V<sub>t</sub> were beneficial for all important outcomes including evolution to ARDS, pneumonia, hospital length of stay, and mortality.<sup>136</sup>

Finally, in brain-dead potential organ donors, a lung protective ventilation strategy maintaining sufficient PEEP and avoiding derecruitment allowed optimization of lung transplant leading to a 2-fold increase in harvested lungs compared with a conventional strategy with the same rate of success and 6-month survival rate.<sup>142</sup>

### VENTILATION IN PATIENTS WITH COPD

Exacerbations of COPD are characterized by a marked worsening of respiratory mechanics secondary to increased airway resistance, expiratory collapse of small airways limiting expiratory flow, development of auto-PEEP and hyperinflation, and increased work of breathing. The development of auto-PEEP has important consequences including increased work of breathing (inspiratory threshold loading), decreased respiratory muscle efficiency (flattened diaphragms), and hemodynamic compromise. Patients are unable to achieve sufficient V<sub>t</sub> despite strong respiratory efforts and have markedly elevated oxygen cost of breathing. In these patients, the physiologic rationale for NIV is very strong—NIV improves ventilatory efficiency, decreases respiratory rate, decreases the work of breathing, and increases alveolar ventilation by increasing V<sub>t</sub>.<sup>143</sup> This approach often improves the patient's level of consciousness.<sup>144</sup> Many studies have found that the use of NIV

can prevent the need for intubation and reduce mortality,<sup>145,146</sup> often in very severe cases.<sup>147-149</sup>

If the patient requires intubation because of a decreased level of consciousness, severe respiratory acidosis despite NIV, or because the initial presentation is too severe for an NIV attempt, the goals of MV can be considered within the context of 2 distinct periods. In the first, often short, period, the aim is to minimize dynamic hyperinflation while obtaining reasonably acceptable values of pH and oxygenation but not normal PaCO<sub>2</sub>. To achieve these goals, the patient usually undergoes ventilation in a controlled pressure or volume mode. The strategy largely consists of minimizing minute ventilation and increasing inspiratory flow to prolong the duration of expiration and permit lung deflation in the presence of a high respiratory system time constant<sup>150</sup> (Figure 2).

In the second period, the major goal is to wean the patient from the ventilator while decreasing the work of breathing. In this period, the patient is allowed to generate spontaneous breathing efforts, often using PSV. Appropriately set external PEEP (just sufficient to overcome auto-PEEP) may help reduce the added elastic load at the start the inspiration. Care must be taken to avoid excessive levels of pressure support (and V<sub>t</sub>), which are associated with lengthening of the inspiratory time and ineffective efforts that are strongly associated with poor outcomes.<sup>151</sup> When the patient undergoes PSV, the level of pressure should be set to decrease the work of breathing but also to limit V<sub>t</sub>; high V<sub>t</sub>s lead to dynamic hyperinflation and ineffective effort, and dyssynchronies are observed very frequently in these patients. Tidal volumes of approximately 6 mL/kg PBW may be necessary to minimize ineffective efforts.<sup>29</sup>

## WEANING

The weaning process can compose as much as 40% of the total duration of MV.<sup>152</sup> However, many uncertainties exist when one tries to describe this phase of the MV journey because various aspects are ill-defined. For example, when does the weaning start? As soon as the patient is intubated, or when the sedation decreased, or when the ventilator is switched to a mode allowing spontaneous breathing?

A common framework is important to enable comparison of weaning duration among groups of patients. Shortening this period is essential because weaning duration is associated with survival.<sup>152</sup> Minimizing sedative drugs<sup>56</sup> and neuromuscular blocking agents to prevent muscle weakness,<sup>20</sup> switching early to a mode of ventilation that allows spontaneous breathing, use of weaning protocols,<sup>153</sup> or even automated weaning<sup>154</sup> are all reasonable strategies to shorten the weaning period.

Determining when a patient can be separated from the ventilator is challenging while the patient is still undergoing MV. Therefore, general criteria have been defined to systematically screen patients for their ability to breathe alone, whatever the ventilator settings. These criteria have challenged the notion that weaning should always be gradual and progressive. How to perform the test to decide for extubation—usually referred to as a spontaneous breathing trial (SBT)—is a matter of debate,<sup>155</sup> as explained below. A recent study classified weaning on the basis of the timing of weaning success after the first separation attempt (defined as an SBT or any extubation attempt)<sup>155</sup> and reported increased mortality for patients having prolonged weaning. Recent guidelines for liberation from MV recommend using protocols for sedation and weaning, mobilization of patients as early as possible, performance of an SBT with PSV rather than a T-piece, cuff leak tests and corticosteroid administration if there is no leak, and prophylactic NIV for patients at high risk for reintubation.<sup>156</sup>

The choice of the appropriate SBT technique is not as simple as it appears. A recent physiologic meta-analysis found that compared with all other SBT modalities, both T-piece and ventilation with no PSV and no PEEP best and equally simulate the patient's postextubation scenario.<sup>157</sup>

After extubation, prophylactic use of NIV may benefit patients at risk for respiratory failure and reintubation, such as elderly patients with COPD or congestive heart failure.<sup>158,159</sup> Noninvasive ventilation in the weaning strategy might reduce the rate of ventilation-acquired pneumonia and mortality.<sup>160</sup> In 2 recent RCTs, the high-flow nasal cannula technique was noninferior to NIV in postextubation settings for patients at high risk for

respiratory failure<sup>161</sup> and even decreased the rate of reintubation for patients at low risk.<sup>162</sup>

### AVENUES FOR IMPROVEMENT

Our understanding of the pathophysiology of acute respiratory diseases, the impact of ventilator settings on dyssynchronies, and the complications of MV have all markedly improved during the past few decades. Nevertheless, many unanswered questions remain. Given the potential iatrogenic consequences of inadequate delivery of MV, one might assume that avoiding invasive MV at any cost would benefit the patient. However, recent data suggest that spontaneous ventilation can also lead to lung injury in patients with high respiratory drive.<sup>163</sup> Patients breathing spontaneously, whether intubated or not, can experience self-inflicted lung injury due to high minute ventilation and increased V<sub>t</sub>.<sup>96,164</sup> Thus, spontaneous ventilation can also be harmful, and very high respiratory drive with the development of very large V<sub>t</sub> may be an indication for intubation with heavy sedation or neuromuscular blocking agents. Identifying which spontaneously breathing patients are at increased risk for this type of injury is an important area of future research.

A promising approach to limiting complications from MV in patients with ARDS or COPD is the use of extracorporeal life support. These techniques range from extracorporeal carbon dioxide removal, which is the least invasive and can be delivered through a relatively small-bore cannula (dual-lumen 13-17Fr diameter) at a blood flow of less than 500 mL/min, to full extracorporeal membrane oxygenation requiring a large venous cannula (with a minimum diameter of 23Fr) to allow flow rates of more than 4 L/min. The relative efficacy of each of these techniques is currently being examined in clinical trials.

### CONCLUSION

Decades of research, progress, and clinical monitoring has led to an increased understanding of the physiology of MV. A conceptual revolution occurred when the goal of MV moved from normalizing blood gas levels to minimizing VILI while maintaining adequate (albeit not necessarily normal) gas exchange. We now know that management

during the acute phase has a strong impact on long-term outcome and disabilities, and this focus on long-term outcomes will be a focus for future research. The MV journey is making progress but is still far from its ultimate destination.

### ACKNOWLEDGMENTS

We thank Dr Lu Chen for providing the tracings used in Figures 1 and 2.

**Abbreviations and Acronyms:** ARDS = acute respiratory distress syndrome; COPD = chronic obstructive pulmonary disease; C<sub>RS</sub> = compliance of the respiratory system; E<sub>RS</sub> = elastance of the respiratory system; FIO<sub>2</sub> = fraction of inspired oxygen; ICU = intensive care unit; MV = mechanical ventilation; NIV = noninvasive ventilation; ΔP = pressure change; PBW = predicted body weight; PEEP = positive end-expiratory pressure; P<sub>0</sub> = initial alveolar pressure; Pplat = plateau pressure; PSV = pressure support ventilation; RCT = randomized controlled trial; SBT = spontaneous breathing trial; SpO<sub>2</sub> = pulse oximetry oxygen saturation; VILI = ventilator-induced lung injury; V<sub>t</sub> = tidal volume

**Potential Competing Interests:** Dr Slutsky is a consultant for Baxter, Novalung/XENIOS AG, and MAQUET Holding B.V. & Co. Dr Brochard's laboratory has received grants or equipment from Covidien (research on PAV), Maquet (NAVA), Fisher Paykel (high flow), Philips (sleep), Air Liquide (Helium, CPR), General Electric (lung volume, ultrasound).

**Correspondence:** Address to Arthur S. Slutsky, MD, Keenan Centre for Biomedical Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital, 209 Victoria St, Room 305, Toronto, ON M5B 1W8, Canada (slutskya@smh.ca).

### REFERENCES

1. Vesalius A. *De humani corporis fabrica*. Basel, Switzerland: Johannes Oporinus; 1543.
2. Slutsky AS. History of mechanical ventilation: from Vesalius to ventilator-induced lung injury. *Am J Respir Crit Care Med*. 2015; 191(10):1106-1115.
3. Drinker P, Shaw LA. An apparatus for the prolonged administration of artificial respiration, I: A design for adults and children. *J Clin Invest*. 1929;7(2):229-247.
4. Ibsen B. The anaesthetist's viewpoint on the treatment of respiratory complications in poliomyelitis during the epidemic in Copenhagen, 1952. *Proc R Soc Med*. 1954;47(1):72-74.
5. Lassen HCA. A preliminary report on the 1952 epidemic of poliomyelitis in Copenhagen with special reference to the treatment of acute respiratory insufficiency. *Lancet*. 1953; 1(6749):37-41.
6. Engström C-G. Treatment of severe cases of respiratory paralysis by the Engström universal respirator. *Br Med J*. 1954;2(4889):666-669.
7. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. *Lancet*. 1967;2(7511):319-323.
8. Ingelstedt S, Jonson B, Nordström L, Olsson SG. A servo-controlled ventilator measuring expired minute volume,

- airway flow and pressure. *Acta Anaesthesiol Scand Suppl.* 1972; 47:7-27.
9. Kacmarek RM. The mechanical ventilator: past, present, and future. *Respir Care.* 2011;56(8):1170-1180.
  10. Mehta AB, Syeda SN, Wiener RS, Walkey AJ. Epidemiological trends in invasive mechanical ventilation in the United States: a population-based study. *J Crit Care.* 2015;30(6):1217-1221.
  11. ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. *JAMA.* 2012;307(23):2526-2533.
  12. Henderson WR, Chen L, Amato MBP, Brochard LJ. Fifty years of research in ARDS: respiratory mechanics in acute respiratory distress syndrome [published online ahead of print March 17, 2017]. *Am J Respir Crit Care Med.* <http://dx.doi.org/10.1164/rccm.201612-2495CI>.
  13. Chatburn RL, El-Khatib M, Mireles-Cabodevila E. A taxonomy for mechanical ventilation: 10 fundamental maxims. *Respir Care.* 2014;59(11):1747-1763.
  14. Laghi F, Tobin MJ. Indications for mechanical ventilation. In: Tobin MJ, ed. *Principles and Practice of Mechanical Ventilation.* 3rd ed. New York, NY: McGraw-Hill Education; 2012:101-135.
  15. Jubran A, Tobin MJ. Pathophysiologic basis of acute respiratory distress in patients who fail a trial of weaning from mechanical ventilation. *Am J Respir Crit Care Med.* 1997;155(3):906-915.
  16. Ward ME, Corbeil C, Gibbons W, Newman S, Macklem PT. Optimization of respiratory muscle relaxation during mechanical ventilation. *Anesthesiology.* 1988;69(1):29-35.
  17. Cinnella G, Conti G, Lofaso F, et al. Effects of assisted ventilation on the work of breathing: volume-controlled versus pressure-controlled ventilation. *Am J Respir Crit Care Med.* 1996;153(3):1025-1033.
  18. Carreaux G, Mancebo J, Mercat A, et al. Bedside adjustment of proportional assist ventilation to target a predefined range of respiratory effort. *Crit Care Med.* 2013;41(9):2125-2132.
  19. Cecchini J, Schmidt M, Demoule A, Similowski T. Increased diaphragmatic contribution to inspiratory effort during neurally adjusted ventilatory assistance versus pressure support: an electromyographic study. *Anesthesiology.* 2014; 121(5):1028-1036.
  20. Dres M, Dubé B-P, Mayaux J, et al. Coexistence and impact of limb muscle and diaphragm weakness at time of liberation from mechanical ventilation in medical intensive care unit patients. *Am J Respir Crit Care Med.* 2017;195(1):57-66.
  21. Chao DC, Scheinhorn DJ, Steam-Hassenpflug M. Patient-ventilator trigger asynchrony in prolonged mechanical ventilation. *Chest.* 1997;112(6):1592-1599.
  22. de Wit M, Pedram S, Best AM, Epstein SK. Observational study of patient-ventilator asynchrony and relationship to sedation level. *J Crit Care.* 2009;24(1):74-80.
  23. Colombo D, Cammarota G, Alemanni M, et al. Efficacy of ventilator waveforms observation in detecting patient-ventilator asynchrony. *Crit Care Med.* 2011;39(11):2452-2457.
  24. Akoumianaki E, Lyazidi A, Rey N, et al. Mechanical ventilation-induced reverse-triggered breaths: a frequently unrecognized form of neuromechanical coupling. *Chest.* 2013;143(4):927-938.
  25. Dres M, Rittayamai N, Brochard L. Monitoring patient-ventilator asynchrony. *Curr Opin Crit Care.* 2016;22(3):246-253.
  26. Thille AW, Rodriguez P, Cabello B, Lellouche F, Brochard L. Patient-ventilator asynchrony during assisted mechanical ventilation. *Intensive Care Med.* 2006;32(10):1515-1522.
  27. Vignaux L, Vargas F, Roeseler J, et al. Patient-ventilator asynchrony during non-invasive ventilation for acute respiratory failure: a multicenter study. *Intensive Care Med.* 2009;35(5):840-846.
  28. Carreaux G, Lyazidi A, Cordoba-Izquierdo A, et al. Patient-ventilator asynchrony during noninvasive ventilation: a bench and clinical study. *Chest.* 2012;142(2):367-376.
  29. Thille AW, Cabello B, Galia F, Lyazidi A, Brochard L. Reduction of patient-ventilator asynchrony by reducing tidal volume during pressure-support ventilation. *Intensive Care Med.* 2008; 34(8):1477-1486.
  30. Blanch L, Villagra A, Sales B, et al. Asynchronies during mechanical ventilation are associated with mortality. *Intensive Care Med.* 2015;41(4):633-641.
  31. Beitler JR, Sands SA, Loring SH, et al. Quantifying unintended exposure to high tidal volumes from breath stacking dysynchrony in ARDS: the BREATHE criteria. *Intensive Care Med.* 2016;42(9):1427-1436.
  32. Yoshida T, Torsani V, Gomes S, et al. Spontaneous effort causes occult pendelluft during mechanical ventilation. *Am J Respir Crit Care Med.* 2013;188(12):1420-1427.
  33. Husain-Syed F, Slutsky AS, Ronco C. Lung-kidney cross-talk in the critically ill patient. *Am J Respir Crit Care Med.* 2016;194(4):402-414.
  34. Blanch L, Quintel M. Lung-brain cross talk in the critically ill. *Intensive Care Med.* 2017;43(4):557-559.
  35. Nolan JP, Kelly FE. Airway challenges in critical care. *Anaesthesia.* 2011;66(suppl 2):81-92.
  36. Jaber S, Jung B, Chanques G. Endotracheal intubation in the ICU. In: Vincent J-L, ed. *Yearbook of Intensive Care and Emergency Medicine.* Berlin, Germany: Springer-Verlag; 2009:313-321.
  37. De Jong A, Molinari N, Terzi N, et al; AzuRéa Network for the Frida-Réa Study Group. Early identification of patients at risk for difficult intubation in the intensive care unit: development and validation of the MACCOCHA score in a multicenter cohort study. *Am J Respir Crit Care Med.* 2013;187(8):832-839.
  38. Baillard C, Fosse J-P, Sebbane M, et al. Noninvasive ventilation improves preoxygenation before intubation of hypoxic patients. *Am J Respir Crit Care Med.* 2006;174(2):171-177.
  39. Brown CA III, Bair AE, Pallin DJ, Walls RM; NEAR III Investigators. Techniques, success, and adverse events of emergency department adult intubations. *Ann Emerg Med.* 2015;65(4):363-370.e1.
  40. Lavery GG, McCloskey BV. The difficult airway in adult critical care. *Crit Care Med.* 2008;36(7):2163-2173.
  41. Hagberg CA, Gabel JC, Connis RT. Difficult Airway Society 2015 guidelines for the management of unanticipated difficult intubation in adults: not just another algorithm [published correction appears in *Br J Anaesth.* 2016;116(2):309]. *Br J Anaesth.* 2015;115(6):812-814.
  42. Schmitt JM, Vieillard-Baron A, Augarde R, Prin S, Page B, Jardin F. Positive end-expiratory pressure titration in acute respiratory distress syndrome patients: impact on right ventricular outflow impedance evaluated by pulmonary artery Doppler flow velocity measurements. *Crit Care Med.* 2001;29(6):1154-1158.
  43. Guyton AC, Lindsey AW, Abemathy B, Richardson T. Venous return at various right atrial pressures and the normal venous return curve. *Am J Physiol.* 1957;189(3):609-615.
  44. Vieillard-Baron A, Schmitt JM, Augarde R, et al. Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: incidence, clinical implications, and prognosis [published correction appears in *Crit Care Med.* 2002;30(3):726]. *Crit Care Med.* 2001;29(8):1551-1555.
  45. Mekontso Dessap A, Boissier F, Charron C, et al. Acute cor pulmonale during protective ventilation for acute respiratory distress syndrome: prevalence, predictors, and clinical impact. *Intensive Care Med.* 2016;42(5):862-870.
  46. Lhéritier G, Legras A, Caille A, et al. Prevalence and prognostic value of acute cor pulmonale and patent foramen ovale in ventilated patients with early acute respiratory distress syndrome: a multicenter study. *Intensive Care Med.* 2013;39(10):1734-1742.
  47. Repessé X, Charron C, Vieillard-Baron A. Acute cor pulmonale in ARDS: rationale for protecting the right ventricle. *Chest.* 2015;147(1):259-265.

48. Mekontso Dessap A, Boissier F, Leon R, et al. Prevalence and prognosis of shunting across patent foramen ovale during acute respiratory distress syndrome. *Crit Care Med*. 2010; 38(9):1786-1792.
49. Papazian L, Forel J-M, Gacouin A, et al; ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. *N Engl J Med*. 2010;363(12):1107-1116.
50. Pisani MA, Murphy TE, Araujo KLB, Slattum P, Van Ness PH, Inouye SK. Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. *Crit Care Med*. 2009;37(1):177-183.
51. Mehta S, Cook D, Devlin JW, et al; SLEAP Investigators; Canadian Critical Care Trials Group. Prevalence, risk factors, and outcomes of delirium in mechanically ventilated adults. *Crit Care Med*. 2015;43(3):557-566.
52. Porhomayon J, El-Solh AA, Adlparvar G, Jaoude P, Nader ND. Impact of sedation on cognitive function in mechanically ventilated patients. *Lung*. 2016;194(1):43-52.
53. Krajčová A, Waldauf P, Anděl M, Duška F. Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports. *Crit Care*. 2015;19:398.
54. Djaiani G, Silverton N, Fedorko L, et al. Dexmedetomidine versus propofol sedation reduces delirium after cardiac surgery: a randomized controlled trial. *Anesthesiology*. 2016; 124(2):362-368.
55. Reade MC, Eastwood GM, Bellomo R, et al; DAHLIA Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group. Effect of dexmedetomidine added to standard care on ventilator-free time in patients with agitated delirium: a randomized clinical trial [published correction appears in *JAMA*. 2016;316(7):775]. *JAMA*. 2016;315(14):1460-1468.
56. Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. *Lancet*. 2008;371(9607):126-134.
57. Minhas MA, Velasquez AG, Kaul A, Salinas PD, Celi LA. Effect of protocolized sedation on clinical outcomes in mechanically ventilated intensive care unit patients: a systematic review and meta-analysis of randomized controlled trials. *Mayo Clin Proc*. 2015;90(5):613-623.
58. Nash G, Blennerhassett JB, Pontoppidan H. Pulmonary lesions associated with oxygen therapy and artificial ventilation. *N Engl J Med*. 1967;276(7):368-374.
59. Santos C, Ferrer M, Roca J, Torres A, Hernández C, Rodríguez-Roisin R. Pulmonary gas exchange response to oxygen breathing in acute lung injury. *Am J Respir Crit Care Med*. 2000;161(1):26-31.
60. Aboab J, Jonson B, Kouatchet A, Taille S, Niklason L, Brochard L. Effect of inspired oxygen fraction on alveolar derecruitment in acute respiratory distress syndrome. *Intensive Care Med*. 2006;32(12):1979-1986.
61. Whalen RE, Saltzman HA, Holloway DH Jr, McIntosh HD, Sieker HO, Brown IW Jr. Cardiovascular and blood gas responses to hyperbaric oxygenation. *Am J Cardiol*. 1965;15: 638-646.
62. Floyd TF, Clark JM, Gelfand R, et al. Independent cerebral vasoconstrictive effects of hyperoxia and accompanying arterial hypocapnia at 1 ATA. *J Appl Physiol (1985)*. 2003;95(6): 2453-2461.
63. Mackenzie GJ, Flenley DC, Taylor SH, McDonald AH, Staunton HP, Donald KW. Circulatory and respiratory studies in myocardial infarction and cardiogenic shock. *Lancet*. 1964; 2(7364):825-832.
64. Kilgannon JH, Jones AE, Shapiro NI, et al; Emergency Medicine Shock Research Network (EMShockNet) Investigators. Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. *JAMA*. 2010; 303(2):2165-2171.
65. Girardis M, Busani S, Damiani E, et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the Oxygen-ICU Randomized Clinical Trial. *JAMA*. 2016;316(15):1583-1589.
66. Levine S, Nguyen T, Taylor N, et al. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. *N Engl J Med*. 2008;358(13):1327-1335.
67. Goligher EC, Fan E, Herridge MS, et al. Evolution of diaphragm thickness during mechanical ventilation: impact of inspiratory effort. *Am J Respir Crit Care Med*. 2015;192(9):1080-1088.
68. Hudson MB, Smuder AJ, Nelson WB, Bruells CS, Levine S, Powers SK. Both high level pressure support ventilation and controlled mechanical ventilation induce diaphragm dysfunction and atrophy. *Crit Care Med*. 2012;40(4):1254-1260.
69. Khalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis*. 2016;63(5):e61-e111.
70. Dreyfuss D, Saumon G. Ventilator-induced lung injury: lessons from experimental studies. *Am J Respir Crit Care Med*. 1998; 157(1):294-323.
71. Brower RG, Lanken PN, MacIntyre N, et al; National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. *N Engl J Med*. 2004;351(4):327-336.
72. Tremblay LN, Slutsky AS. Ventilator-induced lung injury: from the bench to the bedside. *Intensive Care Med*. 2006; 32(1):24-33.
73. Briel M, Meade M, Mercat A, et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. *JAMA*. 2010;303(9):865-873.
74. Slutsky AS, Ranieri VM. Ventilator-induced lung injury [published correction appears in *N Engl J Med*. 2014;370(17): 1668-1669]. *N Engl J Med*. 2013;369(22):2126-2136.
75. Goligher EC, Kavanagh BP, Rubenfeld GD, et al. Oxygenation response to positive end-expiratory pressure predicts mortality in acute respiratory distress syndrome: a secondary analysis of the LOVS and ExPress trials. *Am J Respir Crit Care Med*. 2014;190(1):70-76.
76. Herridge MS, Chu LM, Matte A, et al; RECOVER Program Investigators (Phase I: towards RECOVER); Canadian Critical Care Trials Group. The RECOVER Program: disability risk groups and 1-year outcome after 7 or more days of mechanical ventilation. *Am J Respir Crit Care Med*. 2016; 194(7):831-844.
77. Needham DM, Davidson J, Cohen H, et al. Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders' conference. *Crit Care Med*. 2012;40(2): 502-509.
78. Pandharipande PP, Girard TD, Jackson JC, et al; BRAIN-ICU Study Investigators. Long-term cognitive impairment after critical illness. *N Engl J Med*. 2013;369(14):1306-1316.
79. Parthasarathy S, Tobin MJ. Effect of ventilator mode on sleep quality in critically ill patients. *Am J Respir Crit Care Med*. 2002; 166(11):1423-1429.
80. Córdoba-Izquierdo A, Drouot X, Thille AW, et al. Sleep in hypercapnic critical care patients under noninvasive ventilation: conventional versus dedicated ventilators. *Crit Care Med*. 2013;41(1):60-68.
81. Wilcox ME, Brummel NE, Archer K, Ely EW, Jackson JC, Hopkins RO. Cognitive dysfunction in ICU patients: risk factors, predictors, and rehabilitation interventions. *Crit Care Med*. 2013;41(9, suppl 1):S81-S98.
82. Damuth E, Mitchell JA, Bartock JL, Roberts BW, Trzeciak S. Long-term survival of critically ill patients treated with prolonged mechanical ventilation: a systematic review and meta-analysis. *Lancet Respir Med*. 2015;3(7):544-553.



83. Herridge MS, Tansey CM, Matté A, et al. Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med*. 2011;364(14):1293-1304.
84. Cameron JI, Chu LM, Matte A, et al; RECOVER Program Investigators (Phase I: towards RECOVER); Canadian Critical Care Trials Group. One-year outcomes in caregivers of critically ill patients. *N Engl J Med*. 2016;374(19):1831-1841.
85. Esteban A, Frutos-Vivar F, Muriel A, et al. Evolution of mortality over time in patients receiving mechanical ventilation. *Am J Respir Crit Care Med*. 2013;188(2):220-230.
86. Bellani G, Laffey JG, Pham T, et al; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries [published correction appears in *JAMA*. 2016;316(3):350]. *JAMA*. 2016;315(8):788-800.
87. Richard JCM, Lyazidi A, Akoumianaki E, et al. Potentially harmful effects of inspiratory synchronization during pressure pre-set ventilation. *Intensive Care Med*. 2013;39(11):2003-2010.
88. Caironi P, Cressoni M, Chiumento D, et al. Lung opening and closing during ventilation of acute respiratory distress syndrome. *Am J Respir Crit Care Med*. 2010;181(6):578-586.
89. Suter PM, Fairley B, Isenberg MD. Optimum end-expiratory airway pressure in patients with acute pulmonary failure. *N Engl J Med*. 1975;292(6):284-289.
90. Rittayamai N, Katsios CM, Beloncle F, Friedrich JO, Mancebo J, Brochard L. Pressure-controlled vs volume-controlled ventilation in acute respiratory failure: a physiology-based narrative and systematic review. *Chest*. 2015;148(2):340-355.
91. Bendixen HH, Hedley-Whyte J, Laver MB. Impaired oxygenation in surgical patients during general anesthesia with controlled ventilation: a concept of atelectasis. *N Engl J Med*. 1963;269:991-996.
92. Tobin MJ. Culmination of an era in research on the acute respiratory distress syndrome [editorial]. *N Engl J Med*. 2000;342(18):1360-1361.
93. Brochard LJ, Lellouche F. Pressure-support ventilation. In: Tobin MJ, ed. *Principles and Practice of Mechanical Ventilation*. 3rd ed. New York, NY: McGraw-Hill Education; 2012: 199-225.
94. Beck J, Gottfried SB, Navalesi P, et al. Electrical activity of the diaphragm during pressure support ventilation in acute respiratory failure. *Am J Respir Crit Care Med*. 2001;164(3):419-424.
95. Mascheroni D, Kolobow T, Fumagalli R, Moretti MP, Chen V, Buckhold D. Acute respiratory failure following pharmacologically induced hyperventilation: an experimental animal study. *Intensive Care Med*. 1988;15(1):8-14.
96. Brochard L, Slutsky A, Pesenti A. Mechanical ventilation to minimize progression of lung injury in acute respiratory failure. *Am J Respir Crit Care Med*. 2017;195(4):438-442.
97. Delisle S, Ouellet P, Bellemare P, Tétrault J-P, Arseneault P. Sleep quality in mechanically ventilated patients: comparison between NAVA and PSV modes. *Ann Intensive Care*. 2011;1(1):42.
98. Schmidt M, Kindler F, Cecchini J, et al. Neurally adjusted ventilatory assist and proportional assist ventilation both improve patient-ventilator interaction. *Crit Care*. 2015;19:56.
99. Alexopoulou C, Kondili E, Platakis M, Georgopoulos D. Patient-ventilator synchrony and sleep quality with proportional assist and pressure support ventilation. *Intensive Care Med*. 2013;39(6):1040-1047.
100. Xirouchaki N, Kondili E, Vaporidi K, et al. Proportional assist ventilation with load-adjustable gain factors in critically ill patients: comparison with pressure support. *Intensive Care Med*. 2008;34(11):2026-2034.
101. Demoule A, Clavel M, Rolland-Debord C, et al. Neurally adjusted ventilatory assist as an alternative to pressure support ventilation in adults: a French multicentre randomized trial. *Intensive Care Med*. 2016;42(11):1723-1732.
102. Brander L, Sinderby C, Lecomte F, et al. Neurally adjusted ventilatory assist decreases ventilator-induced lung injury and non-pulmonary organ dysfunction in rabbits with acute lung injury. *Intensive Care Med*. 2009;35(11):1979-1989.
103. Vaporidi K, Babalis D, Chytas A, et al. Clusters of ineffective efforts during mechanical ventilation: impact on outcome. *Intensive Care Med*. 2017;43(2):184-191.
104. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med*. 1994;149(3, pt 1):818-824.
105. Ferguson ND, Fan E, Camporota L, et al. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material [published correction appears in *Intensive Care Med*. 2012;38(10):1731-1732]. *Intensive Care Med*. 2012;38(10):1573-1582.
106. Gattinoni L, Pesenti A, Avalli L, Rossi F, Bombino M. Pressure-volume curve of total respiratory system in acute respiratory failure: computed tomographic scan study. *Am Rev Respir Dis*. 1987;136(3):730-736.
107. Gattinoni L, Pesenti A. The concept of "baby lung". *Intensive Care Med*. 2005;31(6):776-784.
108. Kneyber MCJ, Zhang H, Slutsky AS. Ventilator-induced lung injury: similarity and differences between children and adults. *Am J Respir Crit Care Med*. 2014;190(3):258-265.
109. Cuquemelle E, Pham T, Papon J-F, Louis B, Danin P-E, Brochard L. Heated and humidified high-flow oxygen therapy reduces discomfort during hypoxemic respiratory failure. *Respir Care*. 2012;57(10):1571-1577.
110. Rittayamai N, Tscheikuna J, Rujwitt P. High-flow nasal cannula versus conventional oxygen therapy after endotracheal extubation: a randomized crossover physiologic study. *Respir Care*. 2014;59(4):485-490.
111. Frat J-P, Thille AW, Mercat A, et al; FLORALI Study Group; REVA Network. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. *N Engl J Med*. 2015;372(23):2185-2196.
112. Goligher EC, Slutsky AS. Not just oxygen? mechanisms of benefit from high-flow nasal cannula in hypoxemic respiratory failure. *Am J Respir Crit Care Med*. 2017;195(9):1128-1131.
113. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med*. 2000;342(18):1301-1308.
114. Needham DM, Yang T, Dinglas VD, et al. Timing of low tidal volume ventilation and intensive care unit mortality in acute respiratory distress syndrome: a prospective cohort study. *Am J Respir Crit Care Med*. 2015;191(2):177-185.
115. Hager DN, Krishnan JA, Hayden DL, Brower RG; ARDS Clinical Trials Network. Tidal volume reduction in patients with acute lung injury when plateau pressures are not high. *Am J Respir Crit Care Med*. 2005;172(10):1241-1245.
116. Bein T, Weber-Carstens S, Goldmann A, et al. Lower tidal volume strategy ( $\approx 3$  ml/kg) combined with extracorporeal CO<sub>2</sub> removal versus 'conventional' protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. *Intensive Care Med*. 2013;39(5):847-856.
117. Mercat A, Richard J-CM, Vielle B, et al; Expiratory Pressure (Express) Study Group. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA*. 2008;299(6):646-655.
118. Meade MO, Cook DJ, Guyatt GH, et al; Lung Open Ventilation Study Investigators. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA*. 2008;299(6):637-645.
119. Akoumianaki E, Maggiore SM, Valenza F, et al; PLUG Working Group (Acute Respiratory Failure Section of the European Society of Intensive Care Medicine). The application of

- esophageal pressure measurement in patients with respiratory failure. *Am J Respir Crit Care Med*. 2014;189(5):520-531.
120. Mauri T, Yoshida T, Bellani G, et al; PLeUral pressure working Group (PLUG—Acute Respiratory Failure section of the European Society of Intensive Care Medicine). Esophageal and transpulmonary pressure in the clinical setting: meaning, usefulness and perspectives. *Intensive Care Med*. 2016;42(9):1360-1373.
  121. Talmor D, Sarge T, Malhotra A, et al. Mechanical ventilation guided by esophageal pressure in acute lung injury. *N Engl J Med*. 2008;359(20):2095-2104.
  122. Amato MBP, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med*. 2015;372(8):747-755.
  123. Laffey JG, Bellani G, Pham T, et al; LUNG SAFE Investigators and the ESICM Trials Group. Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: the LUNG SAFE study. *Intensive Care Med*. 2016;42(12):1865-1876.
  124. Guérin C, Reignier J, Richard J-C, et al; PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. *N Engl J Med*. 2013;368(23):2159-2168.
  125. Bloomfield R, Noble DW, Sudlow A. Prone position for acute respiratory failure in adults. *Cochrane Database Syst Rev*. 2015;(11):CD008095.
  126. Brodie D, Bacchetta M. Extracorporeal membrane oxygenation for ARDS in adults. *N Engl J Med*. 2011;365(20):1905-1914.
  127. Combes A, Brodie D, Bartlett R, et al; International ECMO Network (ECMONet). Position paper for the organization of extracorporeal membrane oxygenation programs for acute respiratory failure in adult patients. *Am J Respir Crit Care Med*. 2014;190(5):488-496.
  128. Amal J-M, Paquet J, Wysocki M, et al. Optimal duration of a sustained inflation recruitment maneuver in ARDS patients. *Intensive Care Med*. 2011;37(10):1588-1594.
  129. Fan E, Wilcox ME, Brower RG, et al. Recruitment maneuvers for acute lung injury: a systematic review. *Am J Respir Crit Care Med*. 2008;178(11):1156-1163.
  130. Suzumura EA, Figueiró M, Normilio-Silva K, et al. Effects of alveolar recruitment maneuvers on clinical outcomes in patients with acute respiratory distress syndrome: a systematic review and meta-analysis. *Intensive Care Med*. 2014;40(9):1227-1240.
  131. Young D, Lamb SE, Shah S, et al. High-frequency oscillation for acute respiratory distress syndrome. *N Engl J Med*. 2013;368(9):806-813.
  132. Ferguson ND, Cook DJ, Guyatt GH, et al; OSCILLATE Trial Investigators; Canadian Critical Care Trials Group. High-frequency oscillation in early acute respiratory distress syndrome. *N Engl J Med*. 2013;368(9):795-805.
  133. Meade MO, Young D, Hanna S, et al. Severity of hypoxemia and effect of high frequency oscillatory ventilation in ARDS [published online ahead of print February 28, 2017]. *Am J Respir Crit Care Med*. <http://dx.doi.org/10.1164/rccm.201609-1938OC>.
  134. Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. *Cochrane Database Syst Rev*. 2016;(6):CD002787.
  135. Ruan S-Y, Huang T-M, Wu H-Y, Wu H-D, Yu C-J, Lai M-S. Inhaled nitric oxide therapy and risk of renal dysfunction: a systematic review and meta-analysis of randomized trials. *Crit Care*. 2015;19:137.
  136. Serpa Neto A, Cardoso SO, Manetta JA, et al. Association between use of lung-protective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome: a meta-analysis. *JAMA*. 2012;308(16):1651-1659.
  137. Jaber S, Coisel Y, Chanques G, et al. A multicentre observational study of intra-operative ventilatory management during general anaesthesia: tidal volumes and relation to body weight. *Anaesthesia*. 2012;67(9):999-1008.
  138. Hess DR, Kondili D, Burns E, Bittner EA, Schmidt UH. A 5-year observational study of lung-protective ventilation in the operating room: a single-center experience. *J Crit Care*. 2013;28(4):533.e9-e15.
  139. Futier E, Constantin J-M, Paugam-Burtz C, et al; IMPROVE Study Group. A trial of intraoperative low-tidal-volume ventilation in abdominal surgery. *N Engl J Med*. 2013;369(5):428-437.
  140. Serpa Neto A, Hemmes SNT, Barbas CSV, et al; PROVE Network Investigators. Protective versus conventional ventilation for surgery: a systematic review and individual patient data meta-analysis. *Anesthesiology*. 2015;123(1):66-78.
  141. Serpa Neto A, Simonis FD, Barbas CSV, et al. Association between tidal volume size, duration of ventilation, and sedation needs in patients without acute respiratory distress syndrome: an individual patient data meta-analysis. *Intensive Care Med*. 2014;40(7):950-957.
  142. Mascia L, Pasero D, Slutsky AS, et al. Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial. *JAMA*. 2010;304(23):2620-2627.
  143. Brochard L, Lsabay D, Piquet J, et al. Reversal of acute exacerbations of chronic obstructive lung disease by inspiratory assistance with a face mask. *N Engl J Med*. 1990;323(22):1523-1530.
  144. Scala R, Naldi M, Archinucci I, Coniglio G, Nava S. Noninvasive positive pressure ventilation in patients with acute exacerbations of COPD and varying levels of consciousness. *Chest*. 2005;128(3):1657-1666.
  145. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. *N Engl J Med*. 1995;333(13):817-822.
  146. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multi-centre randomised controlled trial. *Lancet*. 2000;355(9219):1931-1935.
  147. Conti G, Antonelli M, Navalesi P, et al. Noninvasive vs. conventional mechanical ventilation in patients with chronic obstructive pulmonary disease after failure of medical treatment in the ward: a randomized trial. *Intensive Care Med*. 2002;28(12):1701-1707.
  148. Squadrone E, Frigerio P, Fogliati C, et al. Noninvasive vs. invasive ventilation in COPD patients with severe acute respiratory failure deemed to require ventilatory assistance. *Intensive Care Med*. 2004;30(7):1303-1310.
  149. Lindenauer PK, Stefan MS, Shieh M-S, Pekow PS, Rothberg MB, Hill NS. Outcomes associated with invasive and noninvasive ventilation among patients hospitalized with exacerbations of chronic obstructive pulmonary disease. *JAMA Intern Med*. 2014;174(12):1982-1993.
  150. Rossi A, Polese G, Brandi G, Conti G. Intrinsic positive end-expiratory pressure (PEEP). *Intensive Care Med*. 1995;21(6):522-536.
  151. Nava S, Bruschi C, Rubini F, Palo A, Iotti G, Braschi A. Respiratory response and inspiratory effort during pressure support ventilation in COPD patients. *Intensive Care Med*. 1995;21(11):871-879.
  152. McConville JF, Kress JP. Weaning patients from the ventilator. *N Engl J Med*. 2012;367(23):2233-2239.
  153. Blackwood B, Burns KEA, Cardwell CR, O'Halloran P. Protocolized versus non-protocolized weaning for reducing the duration of mechanical ventilation in critically ill adult patients. *Cochrane Database Syst Rev*. 2014;(11):CD006904.
  154. Rose L, Schultz MJ, Cardwell CR, Jovet P, McAuley DF, Blackwood B. Automated versus non-automated weaning for reducing the duration of mechanical ventilation for critically ill adults and children: a cochrane systematic review and meta-analysis. *Crit Care*. 2015;19:48.

155. Béduneau G, Pham T, Schortgen F, et al; WIND (Weaning according to a New Definition) Study Group and the REVA (Réseau Européen de Recherche en Ventilation Artificielle) Network. Epidemiology of weaning outcome according to a new definition: the WIND Study. *Am J Respir Crit Care Med*. 2017;195(6):772-783.
156. Schmidt GA, Girard TD, Kress JP, et al. Official executive summary of an American Thoracic Society/American College of Chest Physicians clinical practice guideline: liberation from mechanical ventilation in critically ill adults. *Am J Respir Crit Care Med*. 2017;195(1):115-119.
157. Sklar MC, Burns K, Rittayamai N, et al. Effort to breathe with various spontaneous breathing trial techniques: a physiological meta-analysis. *Am J Respir Crit Care Med*. 2017;195(11):1477-1485.
158. Nava S, Gregoretti C, Fanfulla F, et al. Noninvasive ventilation to prevent respiratory failure after extubation in high-risk patients. *Crit Care Med*. 2005;33(11):2465-2470.
159. Ferrer M, Sellarés J, Valencia M, et al. Non-invasive ventilation after extubation in hypercapnic patients with chronic respiratory disorders: randomised controlled trial. *Lancet*. 2009;374(9695):1082-1088.
160. Burns KEA, Meade MO, Premji A, Adhikari NKJ. Noninvasive positive-pressure ventilation as a weaning strategy for intubated adults with respiratory failure. *Cochrane Database Syst Rev*. 2013;(12):CD004127.
161. Hernández G, Vaquero C, Colinas L, et al. Effect of postextubation high-flow nasal cannula vs noninvasive ventilation on reintubation and postextubation respiratory failure in high-risk patients: a randomized clinical trial [published corrections appear in JAMA. 2016;316(19):2047-2048 and JAMA. 2017;317(8):858]. *JAMA*. 2016;316(15):1565-1574.
162. Hernández G, Vaquero C, González P, et al. Effect of postextubation high-flow nasal cannula vs conventional oxygen therapy on reintubation in low-risk patients: a randomized clinical trial. *JAMA*. 2016;315(13):1354-1361.
163. Carteaux G, Millán-Guilarte T, De Prost N, et al. Failure of noninvasive ventilation for de novo acute hypoxemic respiratory failure: role of tidal volume. *Crit Care Med*. 2016;44(2):282-290.
164. Yoshida T, Fujino Y, Amato MBP, Kavanagh BP. Spontaneous breathing during mechanical ventilation: risks, mechanisms, and management. *Am J Respir Crit Care Med*. 2017;195(8):985-992.